Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 19;7(4):419-426.
doi: 10.3138/canlivj-2024-0007. eCollection 2024 Dec.

Comparison of the magnetic resonance elastography and FIB-4 (MEFIB) Index and vibration-controlled transient elastography for significant metabolic dysfunction-associated steatotic liver disease fibrosis

Affiliations

Comparison of the magnetic resonance elastography and FIB-4 (MEFIB) Index and vibration-controlled transient elastography for significant metabolic dysfunction-associated steatotic liver disease fibrosis

Chinmay Bera et al. Can Liver J. .

Abstract

Background: Significant fibrosis (≥stage 2) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is considered a high risk for morbidity and mortality. The magnetic resonance elastography (MRE) and FIB-4 (MEFIB) Index (MRE ≥ 3.3 kPa and FIB-4 ≥ 1.6) has been proposed as an alternative to liver biopsy, particularly in identifying patients for therapeutic intervention. However, MRE is not widely available. Our aim was to compare the MEFIB Index with other simpler, non-invasive markers.

Methods: A single-centre retrospective analysis of steatotic liver disease patients with MRE and vibration-controlled transient elastography (VCTE) was carried out between March 2019 and June 2022. Demographic and laboratory data were collected to calculate various fibrosis scores.

Results: Our cohort included 77 patients with a mean ± SD age of 51 ± 13 years, 44/77 (57%) female, BMI 34.5 ± 6.7 kg/m2, and 33/77 (43%) with diabetes mellitus. Significant MEFIB Index fibrosis (F2-4) compared with F0-1 was significantly associated with older age (61.6 versus 48.9 years), higher VCTE score (18.2 versus 10.6 kPa), NAFLD Fibrosis Score (0.11 versus -1.68), and Aspartate Aminotransferase-To-Platelet Ratio Index (APRI; 1.43 versus 0.44). A logistic regression model showed that age (odds ratio [OR]: 1.16; 95% CI: 1.05-1.29; p = 0.005) and APRI (OR: 10.86; 95% CI: 1.56-75.68; p = 0.016) were independently associated with MEFIB Index and predicted MEFIB F ≥ 2 with an area under the receiver operating characteristic curve of 0.95 (95% CI: 0.87-0.98).

Conclusions: In patients with MASLD, simple clinical and biochemical parameters may provide an alternative to predict significant fibrosis based on the MEFIB score. This may be useful in non-tertiary centres where VCTE and MRE are not routinely available.

Keywords: MR elastography; fatty liver; liver fibrosis; non-invasive test; steatosis; transient elastography.

Plain language summary

Lay Summary: Metabolic dysfunction–associated steatotic liver disease (MASLD), earlier known as non-alcoholic fatty liver disease, is a growing global health concern that is becoming more prevalent. There has always been a search for an accurate non-invasive imaging or blood test to identify patients with metabolic dysfunction–associated steatohepatitis (MASH) and advanced fibrosis. There has been a constant effort to develop a combination of serum- and imaging-based tests to diagnose fibrosis stages without the need for a liver biopsy. Unfortunately, magnetic resonance (MR) elastography (MRE) is not readily accessible and comes at a high cost. In this study, we validated simple clinical and laboratory parameters to predict MRE and FIB-4 Index (MEFIB) scores in our MASLD cohort. We developed a simple test that incorporates age and the Aspartate Aminotransferase-To-Platelet Ratio Index (APRI), which can diagnose advanced fibrosis at an accuracy of over 80%. In conclusion, this study provides a simple alternative to diagnose advanced MASH fibrosis based on the MEFIB index.

PubMed Disclaimer

Conflict of interest statement

N/A

Figures

Figure 1:
Figure 1:
Box showing median, 25th, and 75th percentiles, and whisker plots representing minimal and maximal values. Patients with F2–4 were older than patients with F0–1 (p < 0.0002)
Figure 2:
Figure 2:
Box showing median, 25th, and 75th percentiles, and whisker plots representing minimal and maximal values. Patients with F2–4 had a significantly higher APRI compared with patients with F0–1 (p < 0.0001)

Similar articles

References

    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L.. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47. 10.1097/HEP.0000000000000004. Medline: - DOI - PMC - PubMed
    1. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. 10.1002/hep.20701. Medline: - DOI - PubMed
    1. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65. 10.1002/hep.29085. Medline: - DOI - PMC - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. 10.1002/hep.29367. Medline: - DOI - PubMed
    1. Khalifa A, Rockey DC.. The utility of liver biopsy in 2020. Curr Opin Gastroenterol. 2020;36(3):184–91. 10.1097/MOG.0000000000000621. Medline: - DOI - PMC - PubMed

LinkOut - more resources